CD8A and cancer: These data suggest differences in antigen processing by CpG and nanovaccines for CD8+ T cell epitopes, which in this case have identified HPV08 as a suitable peptide target to be used for the development a peptide based nanovaccine to elicit HPV05 responses against cancers induced by HPV16-E7.